MAPK3 and neoplasm: In order to validate the functional enrichment analyses, we performed phosphorylated ERK1/2 (pERK1/2) IHC, as well as pan-cytokeratin (CK) and vimentin (VIM) IHC, to demonstrate downstream MAPK pathway activation and EMT reprogramming of tumor cells, respectively.